产品集中

Q2 Chemistry Journal of Biomolecular Screening Pub Date : 2005-02-01 DOI:10.1177/108705710501000111

Assay ReagentsSupplies

{"title":"产品集中","authors":"Assay ReagentsSupplies","doi":"10.1177/108705710501000111","DOIUrl":null,"url":null,"abstract":"division. This antibody is targeted against human cyclophilin A, which is thought to play an important role in the mechanism of protein folding. Non-animal-based and in vitro–generated recombinant antibodies are new to the research markets and seem to have several advantages over traditional antibodies. They can be generated within 8 weeks from only a minimum amount of protein, DNA, or peptide. In addition, in vitro–generated antibodies allow for high-throughput production, thus facilitating the development of novel array platforms.","PeriodicalId":15087,"journal":{"name":"Journal of Biomolecular Screening","volume":"10 1","pages":"80 - 84"},"PeriodicalIF":0.0000,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/108705710501000111","citationCount":"0","resultStr":"{\"title\":\"Product Focus\",\"authors\":\"Assay ReagentsSupplies\",\"doi\":\"10.1177/108705710501000111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"division. This antibody is targeted against human cyclophilin A, which is thought to play an important role in the mechanism of protein folding. Non-animal-based and in vitro–generated recombinant antibodies are new to the research markets and seem to have several advantages over traditional antibodies. They can be generated within 8 weeks from only a minimum amount of protein, DNA, or peptide. In addition, in vitro–generated antibodies allow for high-throughput production, thus facilitating the development of novel array platforms.\",\"PeriodicalId\":15087,\"journal\":{\"name\":\"Journal of Biomolecular Screening\",\"volume\":\"10 1\",\"pages\":\"80 - 84\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/108705710501000111\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biomolecular Screening\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/108705710501000111\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Chemistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomolecular Screening","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/108705710501000111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Chemistry","Score":null,"Total":0}

引用次数: 0

摘要

部门。该抗体针对人亲环蛋白A，该蛋白被认为在蛋白质折叠机制中起重要作用。非动物基础和体外生成的重组抗体是研究市场上的新事物，似乎比传统抗体有几个优势。它们可以在8周内由最少量的蛋白质、DNA或肽生成。此外，体外生成的抗体允许高通量生产，从而促进了新型阵列平台的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Product Focus

division. This antibody is targeted against human cyclophilin A, which is thought to play an important role in the mechanism of protein folding. Non-animal-based and in vitro–generated recombinant antibodies are new to the research markets and seem to have several advantages over traditional antibodies. They can be generated within 8 weeks from only a minimum amount of protein, DNA, or peptide. In addition, in vitro–generated antibodies allow for high-throughput production, thus facilitating the development of novel array platforms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Biomolecular Screening 生物-分析化学

CiteScore

2.41

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Advancing the Science of Drug Discovery: SLAS Discovery reports how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Discovery is a peer-reviewed journal that publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery emphasizes scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles on target biology, new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.